Your browser doesn't support javascript.
loading
Emodin in cardiovascular disease: The role and therapeutic potential.
Guo, Yuanyuan; Zhang, Rongzhen; Li, Wenlan.
Afiliación
  • Guo Y; School of Pharmacy, Harbin University of Commerce, Harbin, China.
  • Zhang R; Department of Cardiology, Geriatrics, and General Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Li W; Department of Heart Failure, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Front Pharmacol ; 13: 1070567, 2022.
Article en En | MEDLINE | ID: mdl-36618923
Emodin is a natural anthraquinone derivative extracted from Chinese herbs, such as Rheum palmatum L, Polygonum cuspidatum, and Polygonum multiflorum. It is now also a commonly used clinical drug and is listed in the Chinese Pharmacopoeia. Emodin has a wide range of pharmacological properties, including anticancer, antiinflammatory, antioxidant, and antibacterial effects. Many in vivo and in vitro experiments have demonstrated that emodin has potent anticardiovascular activity. Emodin exerts different mechanisms of action in different types of cardiovascular diseases, including its involvement in pathological processes, such as inflammatory response, apoptosis, cardiac hypertrophy, myocardial fibrosis, oxidative damage, and smooth muscle cell proliferation. Therefore, emodin can be used as a therapeutic drug against cardiovascular disease and has broad application prospects. This paper summarized the main pharmacological effects and related mechanisms of emodin in cardiovascular diseases in recent years and discussed the limitations of emodin in terms of extraction preparation, toxicity, and bioavailability-related pharmacokinetics in clinical applications.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Plantas_medicinales Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Plantas_medicinales Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China